Antibody architecture and pharmacokinetics. Pembrolizumab is a humanized IgG4 monoclonal antibody with a crystallographically resolved full-length structure, including an Fc geometry in which one CH2 domain is rotated 120° relative to previously reported IgG4 conformations, and a compact hinge region consistent with this unusual geometry. The S228P hinge mutation stabilizes the molecule by preventing IgG4 half-antibody arm exchange, preserving the intended bivalent architecture in vivo. As an IgG4, pembrolizumab has low affinity for complement component C1q and Fc receptors, rendering it devoid of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity; therapeutic activity derives entirely from target blockade rather than Fc effector engagement. After intravenous infusion, pembrolizumab distributes systemically with access to tumor-draining lymph nodes, intratumoral stroma, and peripheral blood lymphocyte pools. Pharmacokinetically, it exhibits a terminal half-life of approximately 26 days, and KEYNOTE-001 ex vivo data showed complete peripheral target engagement commencing at 1 mg/kg, remaining durable for at least 21 days. At pharmacokinetic steady state, plasma concentrations vary between approximately 10 and 300 µg/mL across the dosing interval, supporting sustained receptor occupancy on circulating and tissue-resident lymphocytes.

PD-1 target binding. Pembrolizumab's primary molecular target is PD-1, an inhibitory checkpoint receptor expressed on activated T cells, NK cells, and antigen-presenting cells. Crystallographic analysis confirms that hPD-1 and the pembrolizumab Fab form a 1:1 complex, establishing the stoichiometric basis for receptor antagonism. The interaction is exceptionally tight: biophysical measurements report an apparent dissociation constant of 27 pM, approximately 300,000-fold higher affinity than PD-1 for its natural ligand PD-L1. The antibody epitope on PD-1 consists of discontinuous segments that overlap the PD-L1– and PD-L2–binding surfaces, explaining how pembrolizumab prevents binding of hPD-L1 and hPD-L2 to hPD-1 through steric and conformational exclusion. Critical contact residues include Asp85 of PD-1, which forms a salt bridge with ArgH99 of the Fab; the point mutation D85G abolishes hPD-1 binding to pembrolizumab as determined by ELISA. At the paratope level, CDRs of PemFv interact predominantly with a major groove on PD-1 formed by the CC′FG β-sheet scaffold, stabilized by direct hydrogen bonds, water-mediated polar contacts, salt bridges, and hydrophobic packing.

Downstream signaling consequences. Under physiological conditions, PD-1 ligation by PD-L1 or PD-L2 phosphorylates inhibitory ITIM and ITSM motifs in its cytoplasmic tail, enabling recruitment of SHP-2. The phosphatase SHP-2 preferentially dephosphorylates CD28 to terminate its signaling cascade, making CD28 — rather than the TCR complex itself — the proximal effector most sensitive to checkpoint suppression. In parallel, PD-1 engagement blocks the induction of PI3K activity, which abrogates downstream Akt phosphorylation and the metabolic, survival, and proliferative programs it coordinates. Consistent with CD28 primacy, biochemical reconstitution confirms that CD28, not the TCR or its associated components, is the most sensitive target of PD-1–SHP-2 dephosphorylation. PD-1 ligation additionally attenuates TCR-proximal propagation directly: it inhibits T-cell receptor–induced phosphorylation of the ZAP70/CD3ζ signalosome, reducing the amplitude and duration of downstream MAPK and PKCθ signaling cascades. The net result is that PD-1/PD-L1 interaction inhibits T-cell proliferation, cytokine production, and cytolytic function, driving effector T cells toward a hypofunctional, exhausted phenotype.

T cell reinvigoration. Pembrolizumab interrupts all of these inhibitory nodes simultaneously by physically excluding PD-L1/PD-L2 from the PD-1 binding site. In chronic infection and tumor models, restoring CD28 costimulatory competency is mechanistically decisive: CD28 costimulation is required for CD8+ T cell proliferation following PD-1 blockade, demonstrating that checkpoint release works through costimulatory restoration rather than TCR signal amplification alone. At the antigen-recognition level, PD-1 signaling normally disrupts the cooperative TCR–pMHC–CD8 trimolecular interaction by reducing TCR–ligand bond number and dwell time; PD-1 blockade therefore stabilizes productive antigen contacts that drive transcriptional reprogramming toward effector and memory differentiation. In chronically stimulated CD4+ T cells co-cultured with dendritic cells, pembrolizumab can restore or surpass the IFN-γ response, confirming that pathway release translates into functional cytokine output.

Clinical translation. This molecular cascade maps onto measurable antitumor immunity. Pembrolizumab shows tumor-agnostic activity in tumors with mismatch-repair deficiency, where elevated neoantigen burden maximizes the neoantigen-specific T cells available for reinvigoration. In clinical non-responders, immunophenotyping reveals higher frequency of PD-1 expression on CD4+ T cells and elevated co-inhibitory receptor TIM-3 on both CD4 and CD8 lineages, consistent with a residual suppressive state that PD-1 blockade alone cannot fully reverse. Pharmacodynamic tracking after treatment shows that retention of CXCR3+ T cells in peripheral blood correlates with failure of IFN-γ–producing effector cells to infiltrate tumors and remodel the intratumoral chemokine milieu — providing a mechanistic link between receptor-level checkpoint blockade and the quality of the downstream antitumor immune response.